The groundbreaking lung cancer immunotherapy drug CIMAvax-EGF is now being studied in the prevention of the disease.
Roswell Park is opening a clinical trial to study the CIMAvax-EGF® vaccine, a cancer treatment that was developed in Cuba. It will be used to treat lung cancer, the most common cause of cancer death worldwide. This vaccine trial is innovative in three significant ways.